Literature DB >> 6284357

Modification of the sensitivity and repair of potentially lethal damage by diethyldithiocarbamate during and following exposure of plateau-phase cultures of mammalian cells to radiation and cis-diamminedichloroplatinum(II).

R G Evans, C Engel, C Wheatley, J Nielsen.   

Abstract

Diethyldithiocarbamate (DDC), a chelating agent known to reduce levels of superoxide dismutase and glutathione peroxidase, appears to protect irradiated monolayers of mammalian cells when present for 1 hr before and during irradiation. To examine a possible cause of this modification, the repair of potentially lethal X-ray damage was examined with and without the presence of DDC in the medium overlying the cells postirradiation. Although little repair was seen in full medium alone when DDC was added to the full medium, the amount of repair was comparable to that seen under optimum repair conditions, that is, in Hanks' balanced salt solution. The t 1/2 of the repair process in Hanks' balanced salt solution or in full medium with DDC added was comparable and of the order of 1 to 1.5 hr. The cis-platinum sensitivity of the monolayers is significantly modified by the addition of DDC, and the nature of the modification is dependent upon the time at which the DDC is added to the cells following initiation of cis-platinum exposure. To investigate a possible reason for this protection by DDC, we examined the repair of potentially lethal cis-platinum damage in the cell monolayers. Minimal repair was noted in the presence of either Hanks' balanced salt solution or full medium, but when DDC was added to the full medium, the repair was tripled, and the t 1/2 of the repair process was approximately 2 hr. The ability of DDC to protect cells from exposure to both X-rays and cis-platinum, together with its augmentation of repair of potentially lethal damage following exposure to each, has broad clinical application and is being actively explored in tumor-bearing mice.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6284357

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

1.  Dithiocarbamate-based coordination compounds as potent proteasome inhibitors in human cancer cells.

Authors:  Daniela Buac; Sara Schmitt; George Ventro; Fathima Rani Kona; Q Ping Dou
Journal:  Mini Rev Med Chem       Date:  2012-10       Impact factor: 3.862

2.  Effect of diethyldithiocarbamate (DDC) on human monocyte function and metabolism.

Authors:  P Conkling; D G Cornwell; A L Sagone
Journal:  Inflammation       Date:  1985-06       Impact factor: 4.092

3.  Disulfiram modulated ROS-MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like properties.

Authors:  N C Yip; I S Fombon; P Liu; S Brown; V Kannappan; A L Armesilla; B Xu; J Cassidy; J L Darling; W Wang
Journal:  Br J Cancer       Date:  2011-04-12       Impact factor: 7.640

4.  Disulfiram (Antabuse) Activates ROS-Dependent ER Stress and Apoptosis in Oral Cavity Squamous Cell Carcinoma.

Authors:  Priyanka Shah O'Brien; Yue Xi; Justin R Miller; Amy L Brownell; Qinghua Zeng; George H Yoo; Danielle M Garshott; Matthew B O'Brien; Anthony E Galinato; Peter Cai; Neha Narula; Michael U Callaghan; Randal J Kaufman; Andrew M Fribley
Journal:  J Clin Med       Date:  2019-05-06       Impact factor: 4.241

5.  The CYP2E1 inhibitor DDC up-regulates MMP-1 expression in hepatic stellate cells via an ERK1/2- and Akt-dependent mechanism.

Authors:  Tianhui Liu; Ping Wang; Min Cong; Youqing Xu; Jidong Jia; Hong You
Journal:  Biosci Rep       Date:  2013-06-05       Impact factor: 3.840

6.  Cell cycle specific radiosensitisation by the disulfiram and copper complex.

Authors:  Mathias Tesson; Giorgio Anselmi; Caitlin Bell; Robert Mairs
Journal:  Oncotarget       Date:  2017-07-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.